司美格鲁肽联合二甲双胍恩格列净治疗2型糖尿病合并非酒精性脂肪性肝病患者疗效及安全分析

Analysis of the Efficacy and Safety of Semaglutide Combined with Metformin and Empagliflozin in the Treatment of Patients with Type 2 Diabetes Combined with Non-alcoholic Fatty Liver Disease

目的 观察司美格鲁肽与二甲双胍恩格列净联合对2型糖尿病(Type 2 Diabetes Mellitus, T2DM)合并非酒精性脂肪性肝病(Non-alcoholic Fatty Liver Disease, NAFLD)患者治疗的临床应用价值。方法 选取2022年5月—2023年5月上海市松江区泗泾医院收治的100例T2DM合并NAFLD患者为研究对象,通过抽签法分为两组,各50例。对照组给予二甲双胍恩格列净,观察组在对照组的基础上加用司美格鲁肽。比较两组的血糖、肝功能、血脂和不良反应。结果 观察组治疗后空腹血糖、餐后2 h血糖、丙氨酸氨基转移酶、门冬氨酸氨基转移酶、谷氨酰转肽酶、总胆固醇、三酰甘油水平低于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 二甲双胍恩格列净联合司美格鲁肽治疗T2DM合并NAFLD患者,能调节糖脂代谢异常情况,改善其肝功能,安全性可靠。

Objective To observe the clinical application value of semaglutide combined with metformin and empa-gliflozin in the treatment of patients with Type 2 Diabetes Mellitus(T2DM)combined with Non-Alcoholic Fatty Liver Disease(NAFLD).Methods A total of 100 patients with T2DM complicated with NAFLD admitted to Sijing Hospital of Songjiang District of Shanghai from May 2022 to May 2023 were selected as the study objects and divided into two groups with 50 cases each by drawing lots.The control group was given metformin empagliflozin,and the observation group was given semaglutide on the basis of the control group.The blood glucose,liver function,blood lipid and ad-verse reactions were compared between the two groups.Results The levels of fasting blood glucose,2-hour postpran-dial blood glucose,alanine aminotransferase,aspartate aminotransferase,glutamyl transpeptidase,total cholesterol and triglyceride in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Metformin empagliflozin combined with semaglutide can regulate abnormal glu-cose and lipid metabolism and improve liver function in patients with T2DM combined with NAFLD,and is safe and reliable.